(vianews) - vetoquinol (veto.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vetoquinol (veto.pa) | €88.90 | 0.91% | 10.37% |
| biomerieux (bim.pa) | €94.00 | 0.9% | 12.95% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vetoquinol (veto.pa)
0.91% forward dividend yield and 10.37% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.06.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 21.9. meaning, the purchaser of the share is investing €21.9 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.37%.revenue growth
year-on-year quarterly revenue growth grew by 1.2%, now sitting on 539.78m for the twelve trailing months.
dividend yield
as maintained by morningstar, inc., the next dividend payment is on jun 2, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.91%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vetoquinol's stock is considered to be oversold (<=20).
more news about vetoquinol.
2. biomerieux (bim.pa)
0.9% forward dividend yield and 12.95% return on equity
biomérieux s.a. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the americas, europe, the middle east, africa, and the asia pacific. the company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. it also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the biomérieux vision suite name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. the company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. biomérieux s.a. was formerly known as b-d mérieux. the company was founded in 1963 and is headquartered in marcy l'etoile, france. biomérieux s.a. is a subsidiary of institut mérieux sa.
earnings per share
as for profitability, biomerieux has a trailing twelve months eps of €3.82.
pe ratio
biomerieux has a trailing twelve months price to earnings ratio of 24.61. meaning, the purchaser of the share is investing €24.61 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.95%.revenue growth
year-on-year quarterly revenue growth grew by 7.2%, now sitting on 3.59b for the twelve trailing months.
more news about biomerieux.